The International Parkinson's Disease Genomics Consortium (IPDGC) is a collaborative network of researchers dedicated to identifying genetic risk factors for Parkinson's disease. Founded in 2009, the IPDGC has become one of the most influential consortia in PD research, facilitating large-scale genetic studies and enabling precision medicine approaches for drug development.
The IPDGC was established to address the challenges of conducting large-scale genetic studies in Parkinson's disease. By pooling resources, samples, and expertise from multiple institutions worldwide, the consortium has dramatically accelerated the pace of PD genetics discovery.
The IPDGC has led groundbreaking studies identifying novel genetic risk factors for PD:
| Study Type | Key Findings |
|---|---|
| Genome-Wide Association Studies (GWAS) | Identified 90+ risk loci |
| Whole Exome Sequencing | Discovered rare penetrant mutations |
| Whole Genome Sequencing | Found non-coding regulatory variants |
| Multi-ancestry Studies | Expanded understanding to diverse populations |
Genes identified through IPDGC studies have informed drug development:
| Gene | Function | Therapeutic Approach |
|---|---|---|
| LRRK2 | Kinase | LRRK2 inhibitors |
| GBA1 | Enzyme | GBA modulators, chaperone therapy |
| SNCA | Protein aggregation | Alpha-synuclein targeting |
| PRKN | Mitophagy | Parkin activators |
| PINK1 | Mitophagy | PINK1 activators |
The IPDGC's genetic findings enable stratified medicine approaches:
Genetic Subtypes:
The IPDGC brings together over 80 institutions globally:
| Region | Representative Institutions |
|---|---|
| North America | NIH, Mount Sinai, Columbia University, University of Pennsylvania |
| Europe | Wellcome Sanger Institute, UCL, University of Tübingen |
| Asia-Pacific | RIKEN, Seoul National University |
The consortium operates through specialized working groups:
| Year | Study | Impact |
|---|---|---|
| 2011 | First IPDGC GWAS | Identified 13 risk loci |
| 2014 | Large-scale meta-analysis | 28 risk loci |
| 2019 | GWAS meta-analysis | 90+ risk loci |
| 2021 | Multi-ancestry study | Expanded to diverse populations |
IPDGC genetic discoveries have directly informed clinical trials:
The IPDGC works closely with drug repurposing consortia:
| Consortium | Collaboration Focus |
|---|---|
| Linked Clinical Trials | Genetic stratification for trials |
| NIH Repurposing Program | Target validation |
| Michael J. Fox Foundation | Data sharing, funding |
Genetic stratification enables:
The IPDGC contributes to PPMI, a landmark PD biomarker study:
| Dataset | Samples | Data Type |
|---|---|---|
| IPDGC GWAS | 50,000+ | Genotypes |
| IPDGC WES | 10,000+ | Exomes |
| IPDGC WGS | 5,000+ | Genomes |
Genetic discoveries have illuminated PD pathogenesis:
| Pathway | Genes | Drug Development Status |
|---|---|---|
| LRRK2 signaling | LRRK2 | Phase II/III trials |
| GBA1 function | GBA1 | Preclinical/Phase I |
| Autophagy | PRKN, PINK1 | Preclinical |
| Neuroinflammation | TNF, IL1B | Repurposing trials |
The IPDGC aims to: